Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

被引:486
作者
Argo, Curtis K. [1 ]
Northup, Patrick G. [1 ]
Al-Osaimi, Abdullah M. S. [1 ]
Caldwell, Stephen H. [1 ]
机构
[1] Univ Virginia Hlth Syst, Div Gastroenterol & Hepatol, Charlottesville, VA USA
关键词
Fatty liver; Steatohepatitis; Fibrosis; Cirrhosis; Inflammation; FATTY LIVER-DISEASE; HEPATIC INSULIN-RESISTANCE; PLACEBO-CONTROLLED TRIAL; TERM-FOLLOW-UP; CRYPTOGENIC CIRRHOSIS; VITAMIN-E; NATURAL-HISTORY; HEPATOCELLULAR-CARCINOMA; WEIGHT-LOSS; HISTOLOGICAL PROGRESSION;
D O I
10.1016/j.jhep.2009.03.019
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background/Aims: Non-alcoholic steatohepatitis (NASH) is a growing public health problem. Evaluation of risk factors for fibrosis in NASH will help to target resources to reduce development of cirrhosis. This study had two aims; the first to compile longitudinal histological data to characterize the natural history of fibrosis progression in NASH, and second, to identify predictive factors for progression to advanced fibrosis (stage 3 or greater) in NASH. Methods: Subjects had to have a histological diagnosis compatible with NASH on their initial biopsy, received no intervention of proven histological benefit, and undergone two liver biopsies with at least an interval of one year between them. Results: Ten studies were selected comprising 221 patients. 37.6%,, had progressive fibrosis over a mean follow-up interval of 5.3 years (SD, 4.2 years, median, 3.7 years, range 1.0-21.3 years). Proportional hazards regression analysis demonstrated that age (HR = 0.98, p = 0.009) and inflammation on initial biopsy (any inflammation, HR = 2.5, p = 0.001; grade 1, HR = 2.5, p = 0.001; grade 2, HR = 2.4, p = 0.003) are independent predictors of progression to advanced fibrosis. Other traditional parameters (e.g. obesity, diabetes, hypertension) were not statistically significant predictors. Conclusions: Presence of inflammation on the initial biopsy and age are independent predictors of progression to advanced fibrosis in patients with NASH. (C) 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:371 / 379
页数:9
相关论文
共 88 条
[1]
SAMPLING VARIABILITY ON PERCUTANEOUS LIVER-BIOPSY [J].
ABDI, W ;
MILLAN, JC ;
MEZEY, E .
ARCHIVES OF INTERNAL MEDICINE, 1979, 139 (06) :667-669
[2]
Acosta RC, 2001, GASTROENTEROLOGY, V120, pA546, DOI 10.1016/S0016-5085(08)82715-1
[3]
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies [J].
Adams, LA ;
Sanderson, S ;
Lindor, KD ;
Angulo, P .
JOURNAL OF HEPATOLOGY, 2005, 42 (01) :132-138
[4]
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[5]
Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[6]
Cryptogenic cirrhosis: Clinicopathologic findings at and after liver transplantation [J].
Ayata, G ;
Gordon, FD ;
Lewis, D ;
Pomfret, E ;
Pomposelli, JJ ;
Jenkins, RL ;
Khettry, U .
HUMAN PATHOLOGY, 2002, 33 (11) :1098-1104
[7]
NONALCOHOLIC STEATOHEPATITIS - AN EXPANDED CLINICAL ENTITY [J].
BACON, BR ;
FARAHVASH, MJ ;
JANNEY, CG ;
NEUSCHWANDERTETRI, BA .
GASTROENTEROLOGY, 1994, 107 (04) :1103-1109
[8]
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[9]
A low-carbohydrate diet rapidly and dramatically reduces intrahepatic triglyceride content [J].
Browning, Jeffrey D. ;
Davis, Jeannie ;
Saboorian, M. Hossein ;
Burgess, Shawn C. .
HEPATOLOGY, 2006, 44 (02) :487-488
[10]
Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x